Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xlucane vs Lucentis in wAMD
NCT03805100Phase 3Completed
- Sponsor
- Xbrane
- Start
- Apr 2019
- Primary completion
- May 2021
- Modality
- Antibody Fragments
- Countries
- 15
01
Overview
A Phase 3 trial of xlucane in neovascular age-related macular degeneration (NVAMD), sponsored by Xbrane. Started Apr 2019; status: completed.
02
Drugs
xlucane
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03805100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805100.